Medical/Pharmaceuticals
BioDlink Strengthens Global Compliance with Argentina GMP Certification
* Global Milestone: GMP certification from Argentina, marking a key step in its global expansion and regulatory recognition. * Scalable, Trustworthy Solutions: With advanced manufacturing capabilities, BioDlink deliver Pusintin® (bevacizumab) injection that are not only consistent and cost-ef...
2025-06-05 20:30
1941
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded inChicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral present...
2025-06-05 15:41
4157
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has j...
2025-06-05 11:02
2038
Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities
BEIJING, June 4, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDESUSA 2025, the leading international event for oligonucleotide and peptide therapeutics, held inSan Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated "The Great Gene Factory" model,...
2025-06-05 11:01
1966
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 4, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place inChicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being...
2025-06-05 10:46
4093
Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab
HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persist...
2025-06-05 09:36
2046
Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-06-05 08:23
2216
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-06-05 08:00
4160
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2025-06-04 08:00
6188
Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
* Phase IIa study results of Rentosertib were published simultaneously in
NatureMedicine(IF = 58.7) and presented at the American
2025-06-03 22:27
2855
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for regis...
2025-06-03 09:00
1629
Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025
BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensC...
2025-06-03 09:00
1617
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-06-03 09:00
5427
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-06-03 09:00
3598
OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting
CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-gra...
2025-06-02 19:32
1853
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea, June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clini...
2025-06-02 10:22
2279
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene au...
2025-06-02 08:15
1771
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer
SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-06-02 08:00
3637
InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025
NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtini...
2025-06-01 15:00
2249
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, opht...
2025-06-01 09:39
5244
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00